1620 BOX SEQ

Patent Attorney's Docket No. <u>010830-117</u>

6	(PE 40)	
	3 7000	301
2	FEB '	<b>Ö∑</b>
1	TA TRAVE	e Pater

RECEIVED

FEB 1/5 2002 CH CENTER 1600/2900

3	DOLL REAL	IN THE UNITED STATES PATEN	T A	ND TRADEMARK OFFICE	FEB			
TRA	The Patent	Application of	)		TECH CEN			
	••	MASTERNAK et al.	)	Group Art Unit: 1623	ILOHOLN			
	Application	No.: 09/840,243	)	Examiner: Unassigned				
	Filed: Apr	il 24, 2001	)					
	MI CA TR	EW TRANSCRIPTION FACTOR OF HC CLASS II GENES, SUBSTANCES APABLE OF INHIBITING THIS NEW LANSCRIPTION FACTOR AND EDICAL USES OF THESE UBSTANCES	)					
	Assistant (	RESPONSE TO NOTICE TO COMUIREMENTS AND PRELIMINARY A Commissioner for Patents on, D.C. 20231	IPL AM	Y WITH SEQUENCE LISTING ENDMENT TRANSMITTAL I	<u>G</u> LETTER			
	Sir:							
	Enclo Prelimina	osed is a Response to Notice to Comply ry Amendment for the above-identified	wit pate	h Sequence Listing Requirements ent application.	s and			
A Petition for Extension of Time is also enclosed.								
	. []	[ ] A Terminal Disclaimer and a check for [ ] \$55.00 (248) [ ] \$110.00 (148) to cover the requisite Government fee are also enclosed.						
	[X]	Also enclosed is a <u>Declaration Pursuant</u> copy of Sequence Listing, a diskette confidence to Comply dated Decem	:onu	alling the Sequence houng, and	<u>per</u> 1 copy			
	[]	Small entity status is hereby claimed.						
	[]	[ ] Applicant(s) request continued examination under 37 C.F.R. § 1.114 and enclosed [ ] \$370.00 (279) [ ] \$740.00 (179) fee due under 37 C.F.R. § 1.17(e).						
		[ ] Applicant(s) previously submitte requested.	ed	_, on, for which continued ex	xamination is			

- [ ] Applicant(s) request suspension of action by the Office until at least \_, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.
- [ ] A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (146/246) is also enclosed.
- [X] No additional claim fee is required.
- [ ] An additional claim fee is required, and is calculated as shown below:

<b>5</b>	No. OF CLAIMS	HIGHEST NO. OF CLAIMS PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	ADDT'L FEE
Total Claims	76	MINUS 76 =	-0-	$\times$ \$18.00 (103) =	-0-
ndependent Claims	10	MINUS 10 =	-0-	× \$84.00 (102) =	-0-
f Amendment adds mu	iltiple depend	ent claims, add \$280	).00 (104)		
Total Amendment Fee					<u> </u>
If small entity status is	claimed, sub	tract 50% of Total A	mendment Fo	ee	

[ ] A claim fee in the amount of \$\_\_\_\_\_ is enclosed.

[ ] Charge \$\_\_\_\_\_to Deposit Account No. 02-4800.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.


Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Susan M. Dadio Registration No. 40,373

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: February 13, 2002





## United States Patent and Trademark Office

## **TECH CENTER 1600/2900**

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231

Washington, D.C. 2023i www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/840,243

04/24/2001

Krzysztof Masternak

010830-117

21839 BURNS DOANE SWECKER & MATHIS L L P POST OFFICE BOX 1404 ALEXANDRIA, VA 22313-1404 CONFIRMATION NO. 3494
FORMALITIES LETTER

\*OC000000007191693\*

Date Mailed: 12/13/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE